Pharma BD Deal Intelligence
A win with a licensing catch: Merck paid $4B upfront for rights to three Daiichi Sankyo DXd antibody-drug conjugates—patritumab, ifinatamab, and raludotatug deruxtecan—structured to cap risk at $22B total. Daiichi kept Japan, and the deal validated ADCs as pharma's next modality without forcing a single acquisition bet.
Ranks computed across 828 graded deals (Critic + Outcome Score both present).
FDA lifted the U.S. partial clinical hold on the Phase 3 IDeate-Lung02 trial of ifinatamab deruxtecan on Jan 13, 2026; EU hold remained in place.
FDA accepted the BLA and granted Priority Review for I-DXd in previously treated ES-SCLC; PDUFA action date October 10, 2026.
Daiichi Sankyo and Merck announce global development and commercialization collaboration for three Daiichi Sankyo DXd ADCs. Merck will pay a $4 billion upfront…
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
Merck entered a global development and commercialization collaboration with Daiichi Sankyo for three DXd-based ADC candidates, paying $4 billion upfront plus $1.5 billion in continuation payments, with up to $16.5 billion in additional sales milestones (total potential value up to $22 billion); Daiichi Sankyo retains exclusive rights in Japan and is solely responsible for manufacturing. The collaboration was expanded in August 2024 to add gocatamig (MK-6070/DS3280). Outcomes have been mixed: patritumab deruxtecan (HER3-DXd) failed FDA review for NSCLC and was withdrawn. Ifinatamab deruxtecan (I-DXd) had its Phase 3 IDeate-Lung02 trial placed on a U.S. partial clinical hold in late 2025 over excess ILD-related deaths, but the FDA lifted that hold in January 2026 (the EU hold remained), and in April 2026 the FDA accepted I-DXd's BLA for previously treated extensive-stage small cell lung cancer with Priority Review (PDUFA action date October 10, 2026). Raludotatug deruxtecan (R-DXd, CDH6-targeted) completed dose optimization in the REJOICE-Ovarian01 study (5.6 mg/kg selected) and advanced to the Phase 3 portion in platinum-resistant ovarian cancer.
1.9M US cases/yr · $9.7B Global Market · $22B Total Deal Value (incl. milestones)
Antibody-drug conjugates represent one of the fastest-growing classes in oncology, combining targeted delivery with potent cytotoxic payloads. The Merck-Daiichi deal focused on three next-generation DXd-class ADCs targeting EGFR, B7-H3, and CDH6 antigens across multiple solid tumor types including lung, brain, and ovarian cancers.
Daiichi Sankyo's DXd ADC platform was the most prolific in the industry, anchored by Enhertu ($4B+ revenue). This $5.5B deal gave Merck co-development rights to three pipeline ADCs, intensifying competition with AstraZeneca (Daiichi's Enhertu partner) and Gilead (Trodelvy) in the ADC space.
Merck paid $4B upfront for three DXd-based ADC candidates (HER3-DXd, I-DXd, R-DXd).
HER3-DXd failed to win FDA approval for NSCLC; application later withdrawn. Part of Merck & Co. Inc.'s $5.5B deal to acquire Daiichi Sankyo Co. Ltd..
Ifinatamab deruxtecan granted BTD for extensive-stage SCLC with 48.2% ORR. Regulatory step in Merck & Co. Inc.'s acquisition process for Daiichi Sankyo Co. Ltd..
FDA placed hold after higher-than-expected deaths in 500+ patient trial. Part of Merck & Co. Inc.'s $5.5B deal to acquire Daiichi Sankyo Co. Ltd..
FDA lifted the U.S. partial clinical hold on the Phase 3 IDeate-Lung02 trial of ifinatamab deruxtecan; the companies added ILD/pneumonitis mitigation strategies. The EU hold remained in place.
FDA accepted the I-DXd BLA for previously treated extensive-stage small cell lung cancer and granted Priority Review; PDUFA action date October 10, 2026 (based on IDeate-Lung01).
Mixed but partially de-risked: HER3-DXd failed and was withdrawn; I-DXd survived a 2025 U.S. clinical hold (lifted Jan 2026) and reached FDA Priority Review (PDUFA Oct 2026); R-DXd advanced to Phase 3 in ovarian cancer. High-value, late-stage ADC bet still carrying meaningful safety/execution risk.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Merck & Co. Inc. / Daiichi Sankyo Company, Limited (this deal) | 2023 | $22.0B | 68 |
| Merck & Co. Inc. / Acceleron Pharma Inc. | 2021 | $11.5B | 90 |
| Merck & Co. Inc. / Peloton Therapeutics Inc. | 2019 | $2.2B | 88 |
| Merck & Co. Inc. / AstraZeneca PLC | 2017 | $8.5B | 87 |
| Merck & Co. Inc. / Moderna, Inc. | 2022 | $250M | 86 |
| Merck & Co. Inc. / Moderna, Inc. | 2016 | $250M | 84 |
| Merck & Co. Inc. / Eisai Co., Ltd. | 2018 | $5.8B | 83 |
← Browse all deals · How we score deals
More: 2023 deals · Merck & Co. Inc. deals · Oncology deals